Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study

被引:6
作者
Yu, Pengfei [1 ]
Huang, Xingmao [1 ]
Huang, Ling [1 ]
Dai, Gaiguo [1 ]
Xu, Qi [2 ]
Fang, Jingquan [1 ]
Ye, Zeyao [1 ]
Chai, Tengjiao [1 ]
Du, Yian [1 ]
机构
[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Gastr Surg, Hangzhou 310022, Zhejiang, Peoples R China
[2] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Med Oncol, Hangzhou 310022, Zhejiang, Peoples R China
关键词
Gastric cancer; Chemotherapy; Hyperthermic intraperitoneal chemotherapy (HIPEC); Peritoneal metastasis; Prognosis; CYTOREDUCTIVE SURGERY; PERITONEAL PERFUSION; OPEN-LABEL; CLASSIFICATION; COMPLICATIONS; CAPECITABINE; CISPLATIN; EFFICACY; TRIAL;
D O I
10.1007/s00432-023-05019-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Currently, there is a lack of an effective strategy for the prevention of peritoneal metastasis (PM) from locally advanced gastric cancer (AGC). This randomized-controlled study aimed to evaluate the outcome of D2 radical resection with hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally AGC patients. Methods All enrolled patients were randomly assigned to receive HIPEC plus systemic chemotherapy (HIPEC group) or systemic chemotherapy alone (non-HIPEC group) after radical gastrectomy. HIPEC was performed intraperitoneally with cisplatin (40 mg/m(2)) within 72 h after surgery, while systemic chemotherapy based on the SOX regimen (S-1 combined with oxaliplatin) was administered 4-6 weeks after radical surgery. Patterns of recurrence, adverse events, 3-year disease-free survival (DFS), and overall survival (OS) were analyzed. Results A total of 134 patients were enrolled in the present study. The 3-year DFS rate was 73.8% in the HIPEC group, which was significantly higher than that in the non-HIPEC group (61.2%, P = 0.031). The 3-year OS rate was 73.9% in the HIPEC group and 77.6% in the non-HIPEC group, with no significant difference (P = 0.737). PM was the most common distant metastasis in both groups. The occurrence rate of PM in the HIPEC group was statistically lower than that in the non-HIPEC group (20.9% vs. 40.3%, P = 0.015). Grade 3 or 4 adverse events occurred in 19 (14.2%) patients, and there was no significant difference between the two groups. Conclusion Radical surgery followed by HIPEC combined with systemic chemotherapy is a safe and feasible strategy for locally AGC patients and could effectively improve DFS and reduce the occurrence of PM. However, more prospective randomized studies with a large sample size are warranted.
引用
收藏
页码:11491 / 11498
页数:8
相关论文
共 50 条
  • [31] Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study
    Lei Chen
    Chenghai Zhang
    Zhendan Yao
    Ming Cui
    Jiadi Xing
    Hong Yang
    Nan Zhang
    Maoxing Liu
    Kai Xu
    Fei Tan
    Yuzhe Li
    Beihai Jiang
    Xiangqian Su
    BMC Cancer, 21
  • [32] Comparison of D2 and D2 plus radical surgery for advanced distal gastric cancer: a randomized controlled study
    Pengfei Yu
    Yian Du
    Zhiyuan Xu
    Ling Huang
    Xiangdong Cheng
    World Journal of Surgical Oncology, 17
  • [33] Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study
    Pengfei Yu
    Zeyao Ye
    Gaiguo Dai
    Yanqiang Zhang
    Ling Huang
    Yian Du
    Xiangdong Cheng
    BMC Cancer, 20
  • [34] Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study
    Yu, Pengfei
    Ye, Zeyao
    Dai, Gaiguo
    Zhang, Yanqiang
    Huang, Ling
    Du, Yian
    Cheng, Xiangdong
    BMC CANCER, 2020, 20 (01)
  • [35] Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Advanced Ovarian Cancer: A 2-year Survival Analysis Study
    Farzaneh, Farah
    Ashtiani, Azadeh Jafari
    Bohlooli, Mehrdad
    Hosseini, Maryam Sadat
    CURRENT WOMENS HEALTH REVIEWS, 2024, 20 (04)
  • [36] Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study
    Zhang, Xuchen
    Zhang, Chuantao
    Hou, Helei
    Zhang, Yuming
    Jiang, Peng
    Zhou, Hai
    Wang, Lele
    Zhou, Na
    Zhang, Xiaochun
    TRANSLATIONAL ONCOLOGY, 2023, 31
  • [37] Intrathoracic gastric volvulus as a severe, delayed surgical complication after left subphrenic peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian cancer
    Caronna, Roberto
    Sammartino, Paolo
    Framarino, Maria Luisa
    Sollazzo, Bianca Maria
    Meniconi, Roberto Luca
    Chirletti, Piero
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2013, 11
  • [38] Intrathoracic gastric volvulus as a severe, delayed surgical complication after left subphrenic peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian cancer
    Roberto Caronna
    Paolo Sammartino
    Maria Luisa Framarino
    Bianca Maria Sollazzo
    Roberto Luca Meniconi
    Piero Chirletti
    World Journal of Surgical Oncology, 11
  • [39] Neoadjuvant Chemotherapy versus Surgery Alone for Locally Advanced Gastric Cancer: A Retrospective Comparative Study
    Wang, Lin Bo
    Shen, Jian Guo
    Xu, Chao Yang
    Chen, Wen Jun
    Song, Xiang Yang
    Yuan, Xiao Ming
    HEPATO-GASTROENTEROLOGY, 2008, 55 (86-87) : 1895 - 1898
  • [40] Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection
    Kwon, Hyuk-Chan
    Kim, Min Chan
    Kim, Ki Han
    Jang, Jin Seok
    Oh, Sung Yong
    Kim, Sung-Hyun
    Kwon, Kyung A.
    Lee, Suee
    Lee, Hyung Sik
    Kim, Hyo-Jin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2010, 6 (04) : 278 - 285